Q1 2018 13F Holders as of 31 Mar 2018
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
4,979,115
-
Share change
-
+1,246,573
-
Total reported value
-
$23,594,190
-
Put/Call ratio
-
129%
-
Price per share
-
$4.74
-
Number of holders
-
57
-
Value change
-
+$6,247,048
-
Number of buys
-
30
-
Number of sells
-
16
Institutional Holders of GALECTIN THERAPEUTICS INC - COM NEW (GALT) as of Q1 2018
As of 31 Mar 2018,
GALECTIN THERAPEUTICS INC - COM NEW (GALT) was held by
57 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,979,115 shares.
The largest 10 holders included
VANGUARD GROUP INC, D.A. DAVIDSON & CO., Advisor Group, Inc., EAM Investors, LLC, EAM Global Investors LLC, Benchmark Capital Advisors, BlackRock Inc., GEODE CAPITAL MANAGEMENT, LLC, SABBY MANAGEMENT, LLC, and BlueCrest Capital Management Ltd.
This page lists
57
institutional shareholders reporting positions in this security
for the Q1 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.